September 10, 2025Cancer MedicineOpen Access

Comparative Effectiveness of Direct Oral Anticoagulants and Warfarin on Venous Thromboembolism in Cancer Patients

View Full Paper

Ask AI

Bookmark

Authors

HJHye‐In Jung CGClaudia GeueUniversity of Glasgow GCGiorgio Ciminata

Discussion

Member takes

Implication

Retrospective cohort study shows DOACs lower VTE recurrence and major bleeding compared to warfarin in cancer patients, indicating potential benefits of specific DOACs.

Key Points

Patients on DOACs had a 27% lower risk of VTE recurrence compared to those on warfarin.
Analysis revealed a 32% reduction in the risk of major bleeding for patients using DOACs over warfarin.
Subgroup analyses indicated variable risk levels of mortality among different DOACs like rivaroxaban and edoxaban.
Inverse probability treatment weighting was utilized to adjust for confounding variables in this analysis.

Cite This Study

Jung et al. (2025) studied this question.

synapsesocial.com/papers/68d413f8713b0b5dfea61ce4 https://doi.org/10.1002/cam4.71209

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study shows DOACs lower VTE recurrence and major bleeding compared to warfarin in cancer patients, indicating potential benefits of specific DOACs.

Comparative Effectiveness of Direct Oral Anticoagulants and Warfarin on Venous Thromboembolism in Cancer Patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Comparative Effectiveness of Direct Oral Anticoagulants and Warfarin on Venous Thromboembolism in Cancer Patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider